Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05703971 is registered in ClinicalTrials.gov with Genprex, Inc. as lead sponsor.

NCT NCT05703971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05703971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Lead sponsor
Genprex, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 9, 2024
Completion date
June 30, 2028
Enrollment
62 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer extensive stage